UnitedHealth has tumbled over the past three months. Why TD Cowen sees a recovery
TD Cowen upgraded UnitedHealth (UNH) to buy, raising its price target to $455 from $402, citing potential recovery in Optum Health and stronger earnings growth. Shares have fallen 14% in the past three months due to policy headwinds. Analyst Ryan Langston expects mid-high teens EPS growth through 2028, driven by Optum Health and other factors.
How this was made

The 30-second read
Why it matters
The upgrade could trigger a short‑cover rally and attract new buying interest.
Market read
A fresh analyst upgrade with a substantial price‑target increase provides a clear catalyst for UNH and may influence health‑care sector sentiment.
What to watch
Potential regulatory scrutiny of Medicare Advantage could temper upside.
Background
UnitedHealth has fallen 14% over three months amid policy concerns; the upgrade argues the decline is overstated.
Ticker impact
TD Cowen upgraded UnitedHealth to Buy and raised its price target to $455 from $402.
likely upward pressure as investors price in the new target
The upgrade is a fresh, primary disclosure and the target implies ~38% upside from the current price.
Market effects
Positive for the health‑insurance sector as the upgrade may lift peers.
U.S. market may see modest buying in health‑care stocks.
Limited; primarily affects U.S. health‑care investors.
Counterpoint
Some investors may remain cautious given policy headwinds and pending Medicare anti‑fraud rule.
Key entities
- analystTD Cowen
Equity research firm issuing the upgrade.
- companyUnitedHealth Group
Health‑insurance and health‑services conglomerate (ticker UNH).

